Cell Viability and Cytotoxicity Testing

Comprehensive Cell Viability and Cytotoxicity Testing Services – From Routine Viability Counting to High‑Content Imaging and Mechanistic Profiling

The accurate assessment of cell viability and the evaluation of cytotoxic effects are foundational requirements in biomedical research, drug discovery, toxicology, and the quality control of cell‑based products. Whether determining the effect of a novel compound on cancer cell lines, assessing the safety of a medical device, quantifying the potency of a cellular immunotherapy, or monitoring the health of a biopharmaceutical production culture, reliable viability data are essential for decision‑making, regulatory submissions, and product release. However, a cell viability test is not a trivial single‑endpoint measurement; the choice of assay is critically dependent on the cell type, the mechanism of cell death (apoptosis, necrosis, or autophagy), the expected potency of the agent, the sample matrix, and the required throughput and information content. A poorly selected method can lead to underestimation of toxicity, misinterpretation of mechanism, or failure to detect early or sub‑lethal effects. Regulatory guidelines, such as ISO 10993‑5 (for biological evaluation of medical devices), ICH Q2(R1) for bioassay validation, and the US Pharmacopoeia (USP) chapters for cell‑based assays, demand that the test method be validated for its intended use, demonstrating specificity, precision, and robustness. Our ISO/IEC 17025‑accredited and GMP‑compliant laboratory offers a fully integrated cell viability testing platform, encompassing a comprehensive suite of assays – from the classic metabolic‑based methods (e.g., MTT, XTT, WST‑1, and resazurin) and membrane integrity assays (e.g., trypan blue exclusion, LDH release, and propidium iodide staining) to advanced high‑content imaging and real‑time live‑cell analysis. We deliver quantitative, traceable data, detailed kinetic profiles, and expert biological interpretation, enabling you to obtain a complete picture of cellular health and to meet the most stringent regulatory requirements.

1. The Scientific and Regulatory Rationale for Rigorous Cell Viability Testing

Cell viability assays serve multiple critical purposes: (a) to assess the Cytotoxicity of compounds, materials, or leachables (ISO 10993‑5); (b) to determine the potency of cell‑based therapeutics (e.g., CAR‑T cells, mesenchymal stromal cells); (c) to monitor the health and growth of cell cultures in bioprocessing; (d) to characterise the mechanism of cell death (apoptotic, necrotic, or autophagic); (e) to optimise culture conditions; and (f) to perform quality control of raw materials (e.g., sera, growth factors). The choice of assay – whether metabolic (measuring mitochondrial activity), membrane integrity (measuring dye exclusion), or real‑time impedance‑based – must be aligned with the cell type, the expected cytotoxic potency, the time‑course of the effect, and the need for multiplexing. The assay must be validated to demonstrate that it is specific to the viable cell population, free from interference from test compounds (e.g., colour, fluorescence), and capable of detecting the expected changes in viability over the required concentration range. Our service begins with a thorough consultation to design an optimal testing strategy, including the selection of the appropriate endpoints, the definition of the positive and negative controls, and the statistical plan for the analysis of the data.

2. Our Comprehensive Cell Viability Testing Platform – From Basic Screening to Multiplexed Profiling

We maintain a complete suite of validated cell viability and Cytotoxicity assays, all performed in a controlled environment (incubators, biosafety cabinets) with validated cell lines (including ATCC and ECACC stocks) and certified reference materials. Our portfolio includes:

2.1 Metabolic Activity Assays – MTT, XTT, WST‑1, and Resazurin (Alamar Blue)
We perform tetrazolium salt reduction assays (MTT, XTT, WST‑1) and resazurin reduction assays, which measure the activity of mitochondrial dehydrogenases in viable cells. The signal is proportional to the number of metabolically active cells. We carefully optimise the incubation time and the formazan solubilisation (for MTT) to ensure that the assay is in the linear range. We include appropriate blank corrections (cell‑free controls) and positive controls (e.g., a known cytotoxic agent) to validate each assay run. We provide the percentage of viability relative to the untreated control, and, for potency assays, we calculate the IC₅₀/EC₅₀ using a four‑parameter logistic model. We also assess the effect of the test compound on the assay readout (e.g., by measuring the absorbance of the compound itself) and apply corrections if necessary.

2.2 Membrane Integrity Assays – Trypan Blue Exclusion, Propidium Iodide (PI), and 7‑AAD
We perform trypan blue exclusion (manual counting) and fluorescent dye exclusion assays using PI or 7‑aminoactinomycin D (7‑AAD) to quantify the proportion of cells with compromised membranes. For a more detailed profile, we combine Annexin V staining (for phosphatidylserine externalisation) with PI to distinguish between early apoptosis, late apoptosis, and necrosis. We analyse the stained cells using flow cytometry or automated image cytometry, providing percentage distributions and, for adherent cells, a count of the non‑viable cells detached from the surface.

2.3 Lactate Dehydrogenase (LDH) Release Assay – Cytotoxicity by Membrane Leakage
We use a colorimetric LDH release assay to quantify the cytosolic enzyme LDH released into the culture medium upon membrane damage. The assay is simple and non‑radioactive, and it can be performed in the same plate as the metabolic assay for a combined readout. We include the maximum LDH release control (using a lysis buffer) to normalise the results, and we express the Cytotoxicity as a percentage of the maximum release.

2.4 Real‑Time Live‑Cell Analysis – Impedance‑Based and Fluorescence Microscopy
We use real‑time cell analysers (e.g., xCELLigence RTCA) to monitor cell viability and proliferation in real time by measuring the electrical impedance of the cell monolayer. This label‑free method provides a kinetic profile of the cell response to a compound, including the IC₅₀ and the onset time of the effect. We also employ real‑time fluorescence microscopy (e.g., IncuCyte or Operetta) with fluorescent dyes (e.g., Caspase‑3/7 Green Reagent, Annexin V Red) to track apoptotic and necrotic events in the same well over time, providing a dynamic picture of cell health and death kinetics.

2.5 High‑Content Imaging (HCI) – Multiparametric, Sub‑Cellular Analysis
We perform high‑content imaging using multi‑channel fluorescence microscopy (e.g., Operetta CLS or ImageXpress) to simultaneously quantify multiple parameters: cell number, nuclear morphology (apoptotic bodies), mitochondrial membrane potential (using JC‑10 or TMRM), ROS production, and the activation of specific caspases. This provides a rich, multi‑parametric readout of the cellular response to a compound, enabling the distinction between different mechanisms of action. We use automated image analysis (using Harmony or MetaXpress software) to identify and quantify these features in thousands of cells per well, providing statistically robust data.

2.6 ATP Bioluminescence – CellTiter‑Glo and Similar Assays
We use ATP bioluminescence assays (e.g., CellTiter‑Glo) to quantify the amount of cellular ATP, which is a reliable indicator of metabolically active cells. This assay provides a linear response over a wide range of cell numbers and is highly sensitive. We include ATP standard curves to convert the luminescent signal into an absolute ATP concentration (pmol), enabling a direct comparison of the ATP levels between samples. This method is often used for high‑throughput screening and for potency testing of cytostatic compounds.

2.7 Clonogenic Assay – Long‑Term Survival and Proliferative Capacity
For assessing the long‑term survival and proliferative capacity of cells (e.g., after irradiation or treatment with a cytotoxic drug), we perform a colony formation assay. We plate a defined number of cells, allow them to grow for 1‑3 weeks, and then stain and count the colonies (with > 50 cells). We express the data as plating efficiency and surviving fraction, providing a measure of the reproductive integrity of the cells.

3. Advanced Capabilities – Mechanistic Deep‑Dive, Custom Panel Design, and High‑Throughput Screening

For clients requiring a detailed mechanistic characterisation or a high‑level validation of their test system, we offer a suite of customised, research‑grade services that go beyond routine viability testing:

3.1 Apoptosis and Necrosis Panel – Comprehensive Mechanism Profiling
We offer a full apoptosis/necrosis/autophagy profiling panel that includes: (i) Caspase‑3/7 activation (by fluorescent substrate or by flow cytometry); (ii) Annexin V / PI double staining (to distinguish early and late apoptosis); (iii) Mitochondrial membrane potential (ΔΨm) using JC‑1 or TMRM; (iv) Cytochrome c release (by immunofluorescence); and (v) the assessment of autophagy (by LC3‑II accumulation). This comprehensive panel allows us to identify whether the compound induces the canonical apoptotic pathway, the intrinsic (mitochondrial) or extrinsic (death receptor) pathway, or a non‑apoptotic form of cell death.

3.2 High‑Throughput Screening (HTS) – Large‑Scale Compound Evaluation
We perform HTS using 384‑ or 1536‑well plates with automated liquid handling and high‑speed plate readers (absorbance, fluorescence, and luminescence). We can screen up to 10,000 compounds or conditions per day, with a Z′ factor > 0.6 to ensure high assay quality. We provide hit identification, concentration‑response curves, and IC₅₀ values, along with a detailed statistical analysis of the screen quality (e.g., the signal‑to‑noise ratio and the coefficient of variation).

3.3 3D Cell Culture and Spheroid Viability – Testing in a More Physiologically Relevant Model
We assess the viability and Cytotoxicity of compounds on 3D spheroids (e.g., using hanging‑drop or U‑bottom plates) or in organoid cultures. We use confocal microscopy and ATP‑based assays (adapted for 3D cultures) to determine the penetration depth and the effect of the compound on the spheroid size and viability, providing more clinically predictive data than 2D monolayer assays.

3.4 Co‑Culture and Immune‑Cell Mediated Cytotoxicity – CAR‑T and ADCC Assays
We perform co‑culture assays to assess the killing of target cells by immune cells (e.g., CAR‑T cells, NK cells). We use a combination of luciferase‑based target killing (with luciferase‑expressing target cells) and flow cytometry‑based assays (using cell‑specific markers) to quantify specific lysis. We calculate the EC₅₀ of the effector cell concentration and the specific killing percentage at different effector‑to‑target ratios.

3.5 Method Validation According to ICH Q2(R1) and ISO 10993‑5
We perform full method validation for your cell viability assay, including: (a) specificity (confirming that the signal is due to viable cells and not to artefacts); (b) linearity (over the cell density range relevant to the assay); (c) accuracy (by spike‑and‑recovery experiments with a known number of viable cells); (d) precision (intra‑ and inter‑assay variability); (e) limit of detection (LOD) and limit of quantification (LOQ) for the viability readout; and (f) robustness to variations in incubation time, temperature, or reagent concentrations. The validation report is structured for regulatory submissions.

4. Data Integrity, Standardisation, and Comprehensive Reporting

All analyses are conducted under a strict quality management system that includes the use of validated cell lines, routine positive and negative controls, and participation in proficiency testing (where available). Our reports provide:

• Full method description – including the cell line, culture conditions, assay principle (e.g., MTT reduction), reagent concentrations, and incubation times.
• Detailed results – including the percentage of viability, IC₅₀/EC₅₀ values (with 95% confidence intervals), and, for kinetic assays, the time‑course data.
• Validation data – including the linearity, precision, accuracy, and robustness results, and a clear statement of the assay’s performance.
• Graphical outputs – dose‑response curves, concentration‑response plots, and any relevant images (phase contrast, fluorescence, or high‑content images).
• Interpretative comments – on the significance of the results, the mechanism of action (where discernible), and any recommendations for further studies.

Our reports are authored by senior cell biologists and pharmacologists who provide not just raw data, but contextual insights to guide your development, safety, or research decisions.

Turnaround times: 2‑5 working days for standard viability assays, 1‑2 weeks for comprehensive mechanistic panels, and 2‑3 weeks for method validation. Express services are available for urgent projects.

5. Our Unmatched Expertise – Why Choose Our Laboratory for Cell Viability Testing

We are one of the few laboratories that hold ISO/IEC 17025 accreditation and GMP compliance for cell viability and Cytotoxicity assays, covering a wide range of cell types (adherent, suspension, primary, and stem cells) and assay platforms. Our integrated infrastructure combines automated liquid handling, high‑throughput plate readers, flow cytometry, high‑content imaging, and real‑time impedance systems – enabling cross‑verification of results and a multifaceted understanding of the cellular response. Our team comprises PhD‑level cell biologists, toxicologists, and bioanalytical scientists with extensive experience in assay development, method validation, and regulatory submissions, and we have a proven track record of supporting products from early discovery through to clinical and commercial phases.

We offer unparalleled flexibility: we accept a wide range of sample types – cell lines, primary cells, cryopreserved cells, or even whole‑blood samples – and we provide customised assay development for novel cell types or unique applications. Our secure online portal enables real‑time tracking, access to raw data, and downloadable certificates.

Our modular pricing ensures cost‑effectiveness: you select the level of analysis – from a simple metabolic viability screen to a comprehensive mechanistic panel – with discounts for routine monitoring programmes and bulk submissions. We also provide training, method transfer, and technical consultancy to help you build or strengthen your internal cell viability testing capabilities.

With a proven history of serving over 90 clients in the pharmaceutical, biotechnology, medical device, and cosmetic sectors, we have enabled our partners to ensure product safety, achieve regulatory compliance, and accelerate development timelines. We invite you to leverage our expertise for your cell viability testing needs.

Contact our technical experts today to discuss your cell system, test compounds, and specific assay requirements. We will design a tailored testing plan and provide a detailed proposal within one business day.